The study examined the predictive capability of organoids in 21 pairs of clinical and ex vivo responses to treatments like paclitaxel for gastroesophageal cancer, EGFR-antibodies for CRC, and TAS-102 for CRC. Here, EGFR is linked to colorectal carcinoma.